ProPepMD
Tirzepatide – 1-Month Supply – 503A Compounded
Tirzepatide – 1-Month Supply – 503A Compounded
Supplier availability · In stock
A consultation with a specialist is required. Your provider will assess whether this product is appropriate and explain the prescription and dispensing process.
An in-person consultation with a RELAX specialist is required to discuss this product. Availability depends on clinical suitability and any applicable prescription requirements.
5mg/mL
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at 5mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. One vial provides a 28-day supply.
10mg/mL
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at 10mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. One vial provides a 28-day supply.
15mg/mL
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at 15mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. One vial provides a 28-day supply.
20mg/mL
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at 20mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. One vial provides a 28-day supply.
25mg/mL
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at 25mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. One vial provides a 28-day supply.
30mg/mL
A dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at 30mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. One vial provides a 28-day supply.
Vial size listed by supplier 2 mL
Supplier availability · In stock
Share
